GENB Generate Biomedicines, Inc.
Fundamentals / CIK 0002100782 / USDGenerate Biomedicines, Inc. reported $515.9M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open GENB in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$404.2M Total debt: $75.34M
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Revenue | $4.22M | $6.31M | $7.22M | $9.63M | $10.13M | $8.82M |
| Research & Development | $82.25M | $64.33M | $57.81M | $62.15M | $59.73M | $46.83M |
| Total Operating Expenses | $95.73M | $77.93M | $71.34M | $72.45M | $70.28M | $56.97M |
| Operating Income | -$91.51M | -$71.61M | -$64.11M | -$62.81M | -$60.15M | -$48.15M |
| EBITDA | -$87.81M | -$68.41M | -$60.84M | -$59.51M | -$56.85M | -$44.74M |
| Interest Income | $4.15M | $4.63M | $2.91M | $3.10M | $3.79M | $4.28M |
| Interest Expense | $192K | $155K | $182K | $253K | $307K | $368K |
| Income Before Tax | -$87.61M | -$67.20M | -$61.69M | -$60.00M | -$56.70M | -$44.26M |
| Income Tax Expense | $49K | $53K | $28K | $34K | $44K | $56K |
| Net Income | -$87.66M | -$67.25M | -$61.45M | -$53.62M | -$52.43M | -$41.69M |
| Basic EPS | -$0.68 | -$0.52 | -$1.07 | -$1.97 | -$1.94 | -$1.62 |
| Diluted EPS | -$0.68 | -$0.52 | -$1.07 | -$1.97 | -$1.94 | -$1.62 |
| Basic Shares Outstanding | 128.5M | 128.2M | 64.9M | 33.0M | 33.0M | 32.8M |
| Diluted Shares Outstanding | 128.5M | 128.2M | 64.9M | 33.0M | 33.0M | 32.8M |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $140.3M | $135.4M | $160.6M | $121.7M |
| Short-Term Investments | $263.9M | $322.1M | $356.1M | $99.85M |
| Cash & Short-Term Investments | $404.2M | $457.4M | $516.6M | $221.5M |
| Total Current Assets | $414.6M | $470.3M | $535.4M | $234.4M |
| Property, Plant & Equipment, Net | $38.65M | $27.30M | $27.84M | $29.15M |
| Other Non-Current Assets | $9.34M | $9.06M | $4.75M | $6.81M |
| Total Non-Current Assets | $101.2M | $91.44M | $90.35M | $95.82M |
| Total Assets | $515.9M | $561.7M | $625.7M | $330.2M |
| Accounts Payable | $7.89M | $5.65M | $7.62M | $3.84M |
| Deferred Revenue (Current) | $7.95M | $12.17M | $17.24M | $21.19M |
| Other Current Liabilities | $3.16M | $2.52M | $2.42M | $2.63M |
| Total Current Liabilities | $82.72M | $56.64M | $58.39M | $82.20M |
| Deferred Revenue (Non-Current) | $0 | $0 | $1.24M | $4.51M |
| Other Non-Current Liabilities | $0 | $0 | $0 | $116K |
| Total Non-Current Liabilities | $52.01M | $49.01M | $52.55M | $59.35M |
| Total Liabilities | $134.7M | $105.6M | $110.9M | $141.6M |
| Total Debt (incl. Leases) | $75.34M | $62.63M | $65.57M | $68.53M |
| Common Stock | $129K | $128K | $128K | $33K |
| Retained Earnings | -$892.7M | -$805.0M | -$737.7M | -$676.3M |
| Accumulated Other Comp. Income | -$264K | -$129K | $24K | $106K |
| Total Stockholders' Equity | $381.2M | $456.0M | $514.8M | -$616.0M |
| Total Equity | $381.2M | $456.0M | $514.8M | -$616.0M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$87.66M | -$67.25M | -$61.71M | -$60.03M | -$56.74M | -$44.31M |
| Depreciation & Amortization | $3.70M | $3.20M | $3.27M | $3.30M | $3.30M | $3.41M |
| Stock-Based Compensation | $8.06M | $8.24M | $6.39M | $4.82M | $5.49M | $4.74M |
| Change in Receivables | $0 | $0 | $0 | -$105K | $59K | -$91K |
| Change in Payables | $2.24M | -$1.95M | $3.75M | $2.09M | $446K | -$597K |
| Operating Cash Flow | -$54.86M | -$57.94M | -$80.39M | -$48.43M | -$48.75M | -$53.18M |
| Capital Expenditure | -$2.15M | -$933K | -$3.78M | -$235K | -$154K | -$751K |
| Free Cash Flow | -$57.01M | -$58.88M | -$84.17M | -$48.66M | -$48.91M | -$53.93M |
| Purchases of Investments | -$147.5M | -$606K | -$321.2M | -$22.22M | -$65.16M | -$77.35M |
| Investing Cash Flow | $56.36M | $33.31M | -$259.9M | $9.18M | -$17.07M | $75.53M |
| Financing Cash Flow | $3.49M | -$579K | $378.9M | $3.79M | -$263K | $20.56M |
| Net Change in Cash | $4.99M | -$25.21M | $38.57M | -$35.46M | -$66.08M | $42.92M |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 5.01x | 8.30x | 9.17x | -- | -- | -- |
| Quick Ratio | 4.89x | 8.08x | 8.85x | -- | -- | -- |
| Debt to Equity | 0.20x | 0.14x | 0.13x | -- | -- | -- |
| Revenue Growth (YoY) | -56.2% | -37.7% | -18.1% | -- | -- | -- |